<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03130000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P07550</UniProt_ID>
  <Seq_Length>413</Seq_Length>
  <Molecule_Weight>46427</Molecule_Weight>
  <KEGG_ID>hsa:154</KEGG_ID>
  <Orthology_ID>K04142</Orthology_ID>
  <Function_Summary>Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.</Function_Summary>
  <Pfam_ID>PF00001:7tm_1</Pfam_ID>
  <Allosteric_Activator_Count>13</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Beta2-adrenoceptor</Alias>
      <Alias>Catecholamine receptor</Alias>
      <Alias>Beta-2 adrenoceptor</Alias>
      <Alias>Beta-2 adrenoreceptor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta2-adrenergic receptors.</Detail>
      <Keyword>Beta2-adrenergic receptor activity</Keyword>
      <Ontology_ID>GO:0004941</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Modulates the activity of a potassium channel.</Detail>
      <Keyword>Potassium channel regulator activity</Keyword>
      <Ontology_ID>GO:0015459</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with norepinephrine, (3,4-dihydroxyphenyl-2-aminoethanol), a hormone secreted by the adrenal medulla and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts of the CNS. It is also the biosynthetic precursor of epinephrine.</Detail>
      <Keyword>Norepinephrine binding</Keyword>
      <Ontology_ID>GO:0051380</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>164</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>220</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>15</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>375</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>159</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>34</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>159</Position>
      <Original>Ile</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>27</Position>
      <Original>Glu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>16</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>G-protein coupled receptor protein signaling pathway</Keyword>
      <Ontology_ID>GO:0007186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.</Detail>
      <Keyword>Positive regulation of MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0043410</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process that inhibits the signaling function of a G-protein coupled receptor by uncoupling the receptor from its downstream G proteins.</Detail>
      <Keyword>Desensitization of G-protein coupled receptor protein signaling pathway by arrestin</Keyword>
      <Ontology_ID>GO:0002032</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the activity of the inactive transmembrane receptor protein tyrosine kinase activity.</Detail>
      <Keyword>Activation of transmembrane receptor protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0007171</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An endocytosis process in which cell surface receptors ensure specificity of transport. A specific receptor on the cell surface binds tightly to the extracellular macromolecule (the ligand) that it recognizes; the plasma-membrane region containing the receptor-ligand complex then undergoes endocytosis, forming a transport vesicle containing the receptor-ligand complex and excluding most other plasma-membrane proteins. Receptor-mediated endocytosis generally occurs via clathrin-coated pits and vesicles.</Detail>
      <Keyword>Receptor-mediated endocytosis</Keyword>
      <Ontology_ID>GO:0006898</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of substances from endosomes to lysosomes.</Detail>
      <Keyword>Endosome to lysosome transport</Keyword>
      <Ontology_ID>GO:0008333</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the addition of ubiquitin groups to a protein.</Detail>
      <Keyword>Positive regulation of protein ubiquitination</Keyword>
      <Ontology_ID>GO:0031398</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>346</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>345</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>382</Position>
      <PTM_Type>4-hydroxyproline</PTM_Type>
    </PTM>
    <PTM>
      <Position>395</Position>
      <PTM_Type>4-hydroxyproline</PTM_Type>
    </PTM>
    <PTM>
      <Position>356</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>355</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>262</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>261</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>141</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>246</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGQPGNGSAFLLAPNGSHAPDHDVTQQRDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSPGRNCSTNDSLL</Protein_Seq>
    <DNA_Seq>CCCGGGTTCAAGAGATTCTCCTGTCTCAGCCTCCCGAGTAGCTGGGACTACAGGTACGTGCCACCACACCTGGCTAATTTTTGTATTTTTAGTAGAGACAAGAGTTACACCATATTGGCCAGGATCTTTTGCTTTCTATAGCTTCAAAATGTTCTTAATGTTAAGACATTCTTAATACTCTGAACCATATGAATTTGCCATTTTGGTAAGTCACAGACGCCAGATGGTGGCAATTTCACATGGCACAACCCGAAAGATTAACAAACTATCCAGCAGATGAAAGGATTTTTTTTAGTTTCATTGGGTTTACTGAAGAAATTGTTTGAATTCTCATTGCATCTCCAGTTCAACAGATAATGAGTGAGTGATGCCACACTCTCAAGAGTTAAAAACAAAACAACAAAAAAATTAAAACAAAAGCACACAACTTTCTCTCTCTGTCCCAAAATACATACTTGCATACCCCCGCTCCAGATAAAATCCAAAGGGTAAAACTGTCTTCATGCCTGCAAATTCCTAAGGAGGGCACCTAAAGTACTTGACAGCGAGTGTGCTGAGGAAATCGGCAGCTGTTGAAGTCACCTCCTGTGCTCTTGCCAAATGTTTGAAAGGGAATACACTGGGTTACCGGGTGTATGTTGGGAGGGGAGCATTATCAGTGCTCGGGTGAGGCAAGTTCGGAGTACCCAGATGGAGACATCCGTGTCTGTGTCGCTCTGGATGCCTCCAAGCCAGCGTGTGTTTACTTTCTGTGTGTGTCACCATGTCTTTGTGCTTCTGGGTGCTTCTGTGTTTGTTTCTGGCCGCGTTTCTGTGTTGGACAGGGGTGACTTTGTGCCGGATGGCTTCTGTGTGAGAGCGCGCGCGAGTGTGCATGTCGGTGAGCTGGGAGGGTGTGTCTCAGTGTCTATGGCTGTGGTTCGGTATAAGTCTGAGCATGTCTGCCAGGGTGTATTTGTGCCTGTATGTGCGTGCCTCGGTGGGCACTCTCGTTTCCTTCCGAATGTGGGGCAGTGCCGGTGTGCTGCCCTCTGCCTTGAGACCTCAAGCCGCGCAGGCGCCCAGGGCAGGCAGGTAGCGGCCACAGAAGAGCCAAAAGCTCCCGGGTTGGCTGGTAAGGACACCACCTCCAGCTTTAGCCCTCTGGGGCCAGCCAGGGTAGCCGGGAAGCAGTGGTGGCCCGCCCTCCAGGGAGCAGTTGGGCCCCGCCCGGGCCAGCCCCAGGAGAAGGAGGGCGAGGGGAGGGGAGGGAAAGGGGAGGAGTGCCTCGCCCCTTCGCGGCTGCCGGCGTGCCATTGGCCGAAAGTTCCCGTACGTCACGGCGAGGGCAGTTCCCCTAAAGTCCTGTGCACATAACGGGCAGAACGCACTGCGAAGCGGCTTCTTCAGAGCACGGGCTGGAACTGGCAGGCACCGCGAGCCCCTAGCACCCGACAAGCTGAGTGTGCAGGACGAGTCCCCACCACACCCACACCACAGCCGCTGAATGAGGCTTCCAGGCGTCCGCTCGCGGCCCGCAGAGCCCCGCCGTGGGTCCGCCCGCTGAGGCGCCCCCAGCCAGTGCGCTTACCTGCCAGACTGCGCGCCATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCGGACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATGTCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAGTTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTGGTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACTTTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGCATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAGTACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTGTCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAAGCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCCATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCCAGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTCCATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGATCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGCACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGATAACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGTTTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTGTGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACAGGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGACCTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGATTCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAAAGCAGTTTTTCTACTTTTAAAGACCCCCCCCCCCCCAACAGAACACTAAACAGACTATTTAACTTGAGGGTAATAAACTTAGAATAAAATTGTAAAAATTGTATAGAGATATGCAGAAGGAAGGGCATCCTTCTGCCTTTTTTATTTTTTTAAGCTGTAAAAAGAGAGAAAACTTATTTGAGTGATTATTTGTTATTTGTACAGTTCAGTTCCTCTTTGCATGGAATTTGTAAGTTTATGTCTAAAGAGCTTTAGTCCTAGAGGACCTGAGTCTGCTATATTTTCATGACTTTTCCATGTATCTACCTCACTATTCAAGTATTAGGGGTAATATATTGCTGCTGGTAATTTGTATCTGAAGGAGATTTTCCTTCCTACACCCTTGGACTTGAGGATTTTGAGTATCTCGGACCTTTCAGCTGTGAACATGGACTCTTCCCCCACTCCTCTTATTTGCTCACACGGGGTATTTTAGGCAGGGATTTGAGGAGCAGCTTCAGTTGTTTTCCCGAGCAAAGGTCTAAAGTTTACAGTAAATAAAATGTTTGACCATGCCTTCATTGCACCTGTTTGTCCAAAACCCCTTGACTGGAGTGCTGTTGCCTCCCCCACTGGAAACCGC</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Others</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ADRB2</Gene_Name>
    <Gene_Alias>ADRB2R; B2AR</Gene_Alias>
    <Gene_ID>154</Gene_ID>
    <Genbank_ACCN>NM_000024</Genbank_ACCN>
    <Protein_ACCN>NP_000015</Protein_ACCN>
    <HGNC_ID>286</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/154</Gene_URL>
    <UCSC_ID>uc003lpr.2</UCSC_ID>
    <EMBL_ID>ENSG00000169252</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Obesity, Association with</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_association_with?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Asthma</Disease_Name>
      <Disease_Detail>Asthma</Disease_Detail>
      <Disease_DB>AST005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/asthma?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Severe, and Type Ii Diabetes</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_severe_and_type_ii_diabetes?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Autosomal Dominant</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_autosomal_dominant?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Essential Hypertension</Disease_Name>
      <Disease_Detail>Essential Hypertension</Disease_Detail>
      <Disease_DB>ESS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/essential_hypertension?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Asthma, Nocturnal</Disease_Name>
      <Disease_Detail>Asthma</Disease_Detail>
      <Disease_DB>AST040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/asthma_nocturnal?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Morbid Obesity</Disease_Name>
      <Disease_Detail>Morbid Obesity</Disease_Detail>
      <Disease_DB>MRB003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/morbid_obesity?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Whim Syndrome</Disease_Name>
      <Disease_Detail>Whim Syndrome</Disease_Detail>
      <Disease_DB>WHM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/whim_syndrome?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pain Disorder</Disease_Name>
      <Disease_Detail>Pain Disorder</Disease_Detail>
      <Disease_DB>PND001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pain_disorder?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Late-Onset</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_late_onset?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Insulin Response</Disease_Name>
      <Disease_Detail>Acute Insulin Response</Disease_Detail>
      <Disease_DB>ACT088</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_insulin_response?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Beta-2-Adrenoreceptor Agonist, Reduced Response to</Disease_Name>
      <Disease_Detail>Beta-2-Adrenoreceptor Agonist, Reduced Response to</Disease_Detail>
      <Disease_DB>BT2002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/beta_2_adrenoreceptor_agonist_reduced_response_to?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thyrotoxic Periodic Paralysis</Disease_Name>
      <Disease_Detail>Thyrotoxic Periodic Paralysis</Disease_Detail>
      <Disease_DB>THY054</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thyrotoxic_periodic_paralysis?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Mild, Early-Onset</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_mild_early_onset?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dilated Cardiomyopathy</Disease_Name>
      <Disease_Detail>Dilated Cardiomyopathy</Disease_Detail>
      <Disease_DB>DLT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dilated_cardiomyopathy?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Variation in</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_variation_in?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Status Asthmaticus</Disease_Name>
      <Disease_Detail>Status Asthmaticus</Disease_Detail>
      <Disease_DB>STT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/status_asthmaticus?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aortic Coarctation</Disease_Name>
      <Disease_Detail>Aortic Disease</Disease_Detail>
      <Disease_DB>ART031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aortic_coarctation?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Early-Onset</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_early_onset?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Mountain Sickness</Disease_Name>
      <Disease_Detail>Acute Mountain Sickness</Disease_Detail>
      <Disease_DB>ACT105</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_mountain_sickness?search=ADRB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Orthostatic Intolerance</Disease_Name>
      <Disease_Detail>Orthostatic Intolerance</Disease_Detail>
      <Disease_DB>ORT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/orthostatic_intolerance?search=ADRB2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <Allosteric_Pathway>
    <Pathway>C118, S193, T205, L379, N418, V83, M117, Y199, L414</Pathway>
    <Method>Normal mode analysis, allosteric coupling analysis.@@ Mutagenesis,Structural analysis</Method>
    <Verified__Residue>C118, S193, T205, L379, N418, V83, M117, Y199, L414</Verified__Residue>
    <PubMed_Title>Balabin IA, et al. Proc Natl Acad Sci U S A. 2009,106(34):14253-14258. @@Gustavo J, et al.Proc Natl Acad Sci U S A. 2010 April 27; 107(17): 7787-7792.</PubMed_Title>
    <PubMed_ID>19706508@@20385837</PubMed_ID>
    <is__ref__img>Yes</is__ref__img>
    <is__display>No</is__display>
    <in__pathway__browse>Yes</in__pathway__browse>
  </Allosteric_Pathway>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of the human beta2 adrenoceptor</PDB_Title>
      <PDB_ID>2R4S</PDB_ID>
      <Resolution>3.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2R4S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.</PubMed_Title>
      <Author>Rasmussen SG, et al.</Author>
      <Journal>Nature. 2007 Nov 15;450(7168):383-7.</Journal>
      <PubMed_ID>17952055</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a Methylated beta2 Adrenergic Receptor-Fab complex</PDB_Title>
      <PDB_ID>3KJ6</PDB_ID>
      <Resolution>3.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3KJ6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor.</PubMed_Title>
      <Author>Bokoch MP, ET AL.</Author>
      <Journal>Nature. 2010 Jan 7;463(7277):108-12.</Journal>
      <PubMed_ID>20054398</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human beta2 adrenoceptor</PDB_Title>
      <PDB_ID>2R4R</PDB_ID>
      <Resolution>3.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2R4R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.</PubMed_Title>
      <Author>Rasmussen SG, et al.</Author>
      <Journal>Nature. 2007 Nov 15;450(7168):383-7.</Journal>
      <PubMed_ID>17952055</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cholesterol bound form of human beta2 adrenergic receptor.</PDB_Title>
      <PDB_ID>3D4S</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3D4S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>CHOLESTEROL $(2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate $(2S)-1-(tert-butylamino)-3-[(4-morpholin- 4-yl-1,2,5-thiadiazol-3-yl)oxy]propan
-2-ol</Ligand_Name>
      <PubMed_Title>A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor.</PubMed_Title>
      <Author>Hanson MA, et al.</Author>
      <Journal>Structure. 2008 Jun;16(6):897-905.</Journal>
      <PubMed_ID>18547522</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>High resolution crystal structure of human B2-adrenergic G protein-coupled receptor.</PDB_Title>
      <PDB_ID>2RH1</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2RH1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>DODECAETHYLENE GLYCOL $ACETAMIDE $1,4-BUTANEDIOL $(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan- 2-ol $CHOLESTEROL $MALTOSE $PALMITIC ACID $SULFATE ION</Ligand_Name>
      <PubMed_Title>High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.</PubMed_Title>
      <Author>Cherezov V, et al.</Author>
      <Journal>Science. 2007 Nov 23;318(5854):1258-65.</Journal>
      <PubMed_ID>17962520</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04970</Pathway_ID>
      <Pathway_Title>Salivary secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04022</Pathway_ID>
      <Pathway_Title>cGMP-PKG signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04261</Pathway_ID>
      <Pathway_Title>Adrenergic signaling in cardiomyocytes</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Circulatory system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01580008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130004</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130006</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130007</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130009</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130010</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130011</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03130012</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>